Curated News
By: NewsRamp Editorial Staff
October 02, 2026
Redwood AI Joins Terry Fox-Funded Oncology AI Project
TLDR
- Redwood AI joins a Terry Fox funded oncology AI project, gaining a strategic edge in causal AI for drug development.
- The project uses causal AI and federated learning to predict first-in-human outcomes from preclinical and clinico-genomic data.
- This collaboration aims to accelerate oncology research and improve patient outcomes by predicting clinical trial success more accurately.
- Redwood AI contributes data integration and physicochemical modelling to SynoGraph, backed by a $3.5 million grant.
Impact - Why it Matters
This collaboration highlights the increasing convergence of artificial intelligence and oncology research, potentially accelerating the development of more accurate predictive models for clinical trials. By integrating causal AI with real-world clinico-genomic data, the project could lead to more efficient and targeted cancer therapies, ultimately improving patient outcomes. For investors, Redwood AI’s involvement in a grant-backed initiative with prestigious academic partners may signal progress in its AI capabilities and open doors to future commercial opportunities in the growing field of AI-driven healthcare solutions.
Summary
Redwood AI (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N, WKN: A422EZ), a developer of AI-powered platforms for critical industries, has been named a co-applicant in a competitive Terry Fox Research Institute grant awarded to advance SynoGraph™, an oncology-focused artificial intelligence platform created by Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ). The September 22 announcement identifies Onco as the lead applicant, with Redwood AI, the Michael Smith Genome Sciences Centre, and the Centre de recherche du CHU de Québec-Université Laval serving as co-applicants. The project, titled “Causal AI to Predict First-in-Human Clinical Outcomes from Preclinical and Real-World Clinico-Genomic Data,” aims to determine whether causal AI methods can enhance predictions of first-in-human clinical outcomes by leveraging both preclinical data and real-world clinico-genomic information.
Under the collaboration, Redwood AI will contribute proprietary data integration and physicochemical modelling methods to expand SynoGraph’s predictive capabilities. The grant supports a project with an estimated budget of $3.5 million and reimburses eligible costs up to 25% of that amount. Academic partners will supply clinico-genomic and imaging data for research using federated learning, a technique intended to support analysis while protecting data privacy. This initiative underscores the growing role of AI in oncology research and the importance of cross-sector partnerships in driving innovation.
Investors and stakeholders can find more details by reading the full announcement at Read More>> and staying updated through the company’s newsroom at https://ibn.fm/RDWCF. The news was disseminated by AINewsWire, a specialized communications platform focused on AI advancements and part of the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Redwood AI Joins Terry Fox-Funded Oncology AI Project
